- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03448224
Behavioral Intervention in Reducing Indoor Tanning
The Development and Evaluation of a Behavioral Intervention to Reduce Indoor Tanning
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
To develop and evaluate an online tailored indoor tanning (IT) intervention based on findings from phase 1.
OUTLINE:
INTERVENTION: Participants are randomized to 1 of 2 groups.
GROUP I: Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
GROUP II: Participants are placed on wait-list and may receive full intervention after follow-up.
After completion of study, patients are followed up at 3 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Use of IT at least 25 times in the past year
- Women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (web-based Indoor Tanning intervention)
Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention.
Participants then receive text messages twice weekly for 4 weeks.
|
Questionnaire
Intervention
|
Active Comparator: Group II (wait-list)
Participants are placed on wait-list and may receive full intervention after follow-up.
|
Questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Prior 2-Month Indoor Tanning Sessions Reported by Participants on a Follow-up Survey
Time Frame: Up to 3 months
|
On the follow-up assessment administered 3 months after the baseline assessment, participants will estimate the number of times they used a tanning bed or booth with tanning lamps in the past 2 months with an open-ended response.
|
Up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived Difficulty (Self-efficacy) in Quitting Tanning
Time Frame: At 3 months post-intervention
|
Measured at post-intervention data collection (3 months post intervention) using single item assessment: "How hard would it be for you to stop using tanning beds/booths?"
(Please answer on a scale for 0-10, where 0 is "Not at all hard", 10 is "Extremely hard").
|
At 3 months post-intervention
|
Sunburns
Time Frame: Up to 3 months
|
On the follow-up assessment administered 3 months after the baseline assessment, participants will estimate the number of times they had a sunburn in the past 2 months with an open-ended response.
|
Up to 3 months
|
Intentions to Use Indoor Tanning
Time Frame: Up to 3 months
|
For tanning intentions, participants indicated how likely they were to use an indoor tanning bed in the next year on a 6-point response scale anchored with 1 = Extremely unlikely and 6 = Extremely likely
|
Up to 3 months
|
Number of Participants Expressing Positive Interest in Changing Tanning
Time Frame: 3 months
|
Interest in changing tanning was assessed using a single item: Would you like to reduce or quit indoor tanning if you could do so easily?
Responses coded as 0 = no and 1 = yes
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 131315 (Other Identifier: Rutgers Cancer Institute of New Jersey)
- P30CA072720 (U.S. NIH Grant/Contract)
- NCI-2018-00063 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- Pro2013003349 (Other Identifier: Rutgers Cancer Institute of New Jersey)
- K07CA175115 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subject
-
Changchun GeneScience Pharmaceutical Co., Ltd.Completed
-
CelltrionCompletedHealthy SubjectKorea, Republic of
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompleted
-
GeneScience Pharmaceuticals Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHealthy SubjectUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Texas A&M UniversityCompletedHealthy SubjectUnited States
-
Whanin Pharmaceutical CompanyCompletedHealthy SubjectKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingHealthy SubjectUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation